✦ LIBER ✦

CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study

✍ Scribed by Köppler, H; Pflüger, KH; Eschenbach, I; Pfab, R; Lennert, K; Wellens, W; Schmidt, M; Gassel, WD; Kolb, T; Hässler, R

Book ID: 109836188
Publisher: Nature Publishing Group
Year: 1989
Tongue: English
Weight: 723 KB
Volume: 60
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1989.224

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sequential versus alternating chemothera

Sequential versus alternating chemotherapy for high grade non-hodgkin's lymphomas: A randomized multicentre trial

✍ H. Köppler; K. H. Pflüger; I. Eschenbach; R. Pfab; J. Birkmann; W. Zeller; E. U. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB

In a multicentre phase 111 trial 146 previously untreated patients with high grade non-Hodgkin's lymphomas stage I1 IV were randomized to receive either four cycles of CHOEP (cyclophosphamide 750 mg/m2 iv d 1, doxorubicin 50 mg/m2 iv d 1, vincristine 2 mg iv d 1, etoposide 100 mg/m2 iv d 3-5, predni

Consolidative involved field radiotherap

Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study

✍ Christoph Oehler-Jänne; Christian Taverna; Nadine Stanek; Laura Negretti; Urs M. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

## Abstract The role of involved field radiation therapy (IF‐RT) after high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for non‐Hodgkin's lymphoma (NHL) has not been conclusively defined. It has been hypothesized that HDC might obviate the need of consolidative IF‐RT. A

Six-week rituximab monoclonal antibody t

Six-week rituximab monoclonal antibody therapy for chemotherapy-pretreated advanced low-grade non-Hodgkin's lymphoma: Efficacy and toxicity of a phase II study

✍ K. Bremer 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 176 KB

Monoclonal antibody therapy with CAMPATH

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

✍ M. Uppenkamp; A. Engert; V. Diehl; D. Bunjes; D. Huhn; G. Brittinger 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 55 KB

High dose chemotherapy with autologous s

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study

✍ Marianne B. Eide; Grete F. Lauritzsen; Gunnar Kvalheim; Arne Kolstad; Unn M. Fag 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 247 KB